RALEIGH — Stem cell therapy company BreStem Therapeutics is looking to raise $2 million, according to a filing with the Securities and Exchange Commission.

The Raleigh-based company has raised $50,000 in equity, so far. The money already raised came from a single investor.

The filing did not disclose what the company intends to use the money for.

BreStem’s stem cell therapy is used for lung regeneration for those with pulmonary fibrosis.

The company’s treatment, Autologous Lung Spheroid Cells Therapy, isolates and expands the source of patients’ already present lung progenitors for cell-based lung regeneration.

Other services offered by BreStem are transbroncial biopsies and intravenous deliveries.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.

Note: This story is from the North Carolina Business News Wire, a service of the UNC-Chapel Hill School of Media and Journalism